SWOG S0016 long-term follow-up data suggest a substantial “cured fraction” in advanced follicular lymphoma treated with chemoimmunotherapy. The analysis estimates a cured fraction of 42% for the overall cohort, with relapse rates dropping to 0.6% after 15 years. The report highlights 15-year progression-free survival of 34% for the R-CHOP arm, and it also notes that adding radioimmunotherapy improved long-term progression-free survival, though no corresponding overall survival benefit emerged. The radioimmunotherapy arm also faced limitations, including an increased rate of myeloid neoplasms. The 15-year results challenge the historical assumption that advanced follicular lymphoma is uniformly incurable, while reinforcing the need to interpret cross-trial comparisons cautiously.